Deerfield Mgmt III, L.P.
Director10% Owner
Deerfield Mgmt III, L.P.Director10% Owner
Deerfield Mgmt III, L.P. insider trades: Larimar Therapeutics (LRMR) stock buys and sales
Director, Larimar Therapeutics Last trade Feb 27, 2026 53 Form 4 filings
$0
Sold, last 12 months
0 sales
$25.0M
Bought, last 12 months
4 buys
114
Open-market trades
since 2014
25
Companies
last trade 2026
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Deerfield Mgmt III, L.P. reports to the SEC
PBLSParabilis Medicines
10% Owner · last filing Jun 11, 2026
No market trades
LRMRLarimar Therapeutics
Director · last filing Mar 2, 2026
+$133.5M
SPRYARS Pharmaceuticals
10% Owner · last filing Jul 1, 2025
-$23.8M
GUTSFractyl Health
10% Owner · last filing Feb 8, 2024
No market trades
ONCROncorus
10% Owner · last filing Dec 30, 2022
-$151K
+$20.7M
AFIBAcutus Medical
Director · last filing Jul 5, 2022
+$42.0M
and 19 more companies
Open-market buys and sales
114 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | LRMR | ↑ Buy | 2,000,000 | $5.00 | $10.0M | Through Deerfield Partners, L.P. | Mar 2, 2026 (3d) |
| Feb 27, 2026 | LRMR | ↑ Buy | 1,084,012 | $5.00 | $5.4M | Through Deerfield Private Design Fund IV | Mar 2, 2026 (3d) |
| Feb 27, 2026 | LRMR | ↑ Buy | 1,084,010 | $5.00 | $5.4M | Through Deerfield Private Design Fund II | Mar 2, 2026 (3d) |
| Feb 27, 2026 | LRMR | ↑ Buy | 831,978 | $5.00 | $4.2M | Through Deerfield Healthcare Innovations | Mar 2, 2026 (3d) |
| Jul 31, 2025 | LRMR | ↑ Buy | 3,387,539 | $3.20 | $10.8M | Through Deerfield Private Design Fund IV | Aug 4, 2025 (4d) |
| Jul 31, 2025 | LRMR | ↑ Buy | 3,387,529 | $3.20 | $10.8M | Through Deerfield Private Design Fund II | Aug 4, 2025 (4d) |
| Jul 31, 2025 | LRMR | ↑ Buy | 2,599,932 | $3.20 | $8.3M | Through Deerfield Healthcare Innovations | Aug 4, 2025 (4d) |
| Jun 27, 2025 | SPRY | ↓ Sell | 370,075 | $18.46 | $6.8M | Through Deerfield Private Design Fund II | Jul 1, 2025 (4d) |
| Jun 27, 2025 | SPRY | ↓ Sell | 370,074 | $18.46 | $6.8M | Through Deerfield Private Design Fund IV | Jul 1, 2025 (4d) |
| Nov 12, 2024 | SPRY | ↓ Sell | 281,635 | $18.01 | $5.1M | Through Deerfield Private Design Fund II | Nov 13, 2024 (1d) |
| Nov 12, 2024 | SPRY | ↓ Sell | 281,635 | $18.01 | $5.1M | Through Deerfield Private Design Fund IV | Nov 13, 2024 (1d) |
| Feb 16, 2024 | LRMR | ↑ Buy | 1,430,206 | $8.74 | $12.5M | Through Deerfield Private Design Fund IV | Feb 16, 2024 (0d) |
| Feb 16, 2024 | LRMR | ↑ Buy | 1,430,206 | $8.74 | $12.5M | Through Deerfield Private Design Fund II | Feb 16, 2024 (0d) |
| Feb 16, 2024 | LRMR | ↑ Buy | 1,430,205 | $8.74 | $12.5M | Through Deerfield Partners, L.P. | Feb 16, 2024 (0d) |
| Dec 30, 2022 | ONCR | ↓ Sell | 149,691 | $0.26 | $39K | Through Deerfield Private Design Fund II | Dec 30, 2022 (0d) |
| Dec 30, 2022 | ONCR | ↓ Sell | 149,690 | $0.26 | $39K | Through Deerfield Healthcare Innovations | Dec 30, 2022 (0d) |
| Dec 30, 2022 | ONCR | ↓ Sell | 36,854 | $0.26 | $10K | Through Deerfield Partners, L.P. | Dec 30, 2022 (0d) |
| Dec 27, 2022 | ONCR | ↓ Sell | 32,670 | $0.27 | $9K | Through Deerfield Private Design Fund II | Dec 27, 2022 (0d) |
| Dec 27, 2022 | ONCR | ↓ Sell | 32,669 | $0.27 | $9K | Through Deerfield Healthcare Innovations | Dec 27, 2022 (0d) |
| Dec 27, 2022 | ONCR | ↓ Sell | 8,045 | $0.27 | $2K | Through Deerfield Partners, L.P. | Dec 27, 2022 (0d) |
| Dec 21, 2022 | ONCR | ↓ Sell | 57,100 | $0.29 | $17K | Through Deerfield Healthcare Innovations | Dec 21, 2022 (0d) |
| Dec 21, 2022 | ONCR | ↓ Sell | 57,099 | $0.29 | $17K | Through Deerfield Private Design Fund II | Dec 21, 2022 (0d) |
| Dec 21, 2022 | ONCR | ↓ Sell | 14,059 | $0.29 | $4K | Through Deerfield Partners, L.P. | Dec 21, 2022 (0d) |
| Dec 15, 2022 | ONCR | ↓ Sell | 6,137 | $0.39 | $2K | Through Deerfield Healthcare Innovations | Dec 15, 2022 (0d) |
| Dec 15, 2022 | ONCR | ↓ Sell | 6,137 | $0.39 | $2K | Through Deerfield Private Design Fund II | Dec 15, 2022 (0d) |
| Dec 15, 2022 | ONCR | ↓ Sell | 1,512 | $0.39 | $585 | Through Deerfield Partners, L.P. | Dec 15, 2022 (0d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Private Design Fund IV | Sep 20, 2022 (4d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Partners, L.P. | Sep 20, 2022 (4d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Private Design Fund II | Sep 20, 2022 (4d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Healthcare Innovations | Sep 20, 2022 (4d) |
| Jul 19, 2021 | AFIB | ↑ Buy | 680,592 | $14.00 | $9.5M | Through Deerfield Private Design Fund II | Jul 21, 2021 (2d) |
| Jul 19, 2021 | AFIB | ↑ Buy | 390,836 | $14.00 | $5.5M | Through Deerfield Partners, L.P. | Jul 21, 2021 (2d) |
| Jun 30, 2021 | LRMR | ↑ Buy | 228,571 | $8.75 | $2.0M | Through Deerfield Private Design Fund IV | Jul 2, 2021 (2d) |
| Jun 30, 2021 | LRMR | ↑ Buy | 228,570 | $8.75 | $2.0M | Through Deerfield Healthcare Innovations | Jul 2, 2021 (2d) |
| Jun 30, 2021 | LRMR | ↑ Buy | 228,569 | $8.75 | $2.0M | Through Deerfield Private Design Fund II | Jul 2, 2021 (2d) |
| Feb 17, 2021 | ONCR | ↑ Buy | 133,558 | $19.00 | $2.5M | Through Deerfield Healthcare Innovations | Feb 18, 2021 (1d) |
| Feb 17, 2021 | ONCR | ↑ Buy | 133,558 | $19.00 | $2.5M | Through Deerfield Private Design Fund II | Feb 18, 2021 (1d) |
| Feb 17, 2021 | ONCR | ↑ Buy | 32,884 | $19.00 | $625K | Through Deerfield Partners, L.P. | Feb 18, 2021 (1d) |
| Jan 8, 2021 | LUMO | ↓ Sell | 151,723 | $22.58 | $3.4M | Through Deerfield Private Design Fund II | Jan 8, 2021 (0d) |
| Oct 6, 2020 | ONCR | ↑ Buy | 445,194 | $15.00 | $6.7M | Through Deerfield Healthcare Innovations | Oct 8, 2020 (2d) |
| Oct 6, 2020 | ONCR | ↑ Buy | 445,194 | $15.00 | $6.7M | Through Deerfield Private Design Fund II | Oct 8, 2020 (2d) |
| Oct 6, 2020 | ONCR | ↑ Buy | 109,612 | $15.00 | $1.6M | Through Deerfield Partners, L.P. | Oct 8, 2020 (2d) |
| Sep 29, 2020 | GRAY | ↑ Buy | 1,562,500 | $16.00 | $25.0M | Through Deerfield Partners, L.P. | Oct 1, 2020 (2d) |
| Aug 10, 2020 | AFIB | ↑ Buy | 944,444 | $18.00 | $17.0M | Through Deerfield Partners, L.P. | Aug 12, 2020 (2d) |
| Aug 10, 2020 | AFIB | ↑ Buy | 555,556 | $18.00 | $10.0M | Through Deerfield Private Design Fund II | Aug 12, 2020 (2d) |
| Jan 30, 2020 | FIXX | ↓ Sell | 518,827 | $15.45 | $8.0M | Through Deerfield Partners, L.P. | Jan 31, 2020 (1d) |
| Jan 28, 2020 | FIXX | ↓ Sell | 639,506 | $15.69 | $10.0M | Through Deerfield Partners, L.P. | Jan 28, 2020 (0d) |
| Dec 24, 2019 | FIXX | ↓ Sell | 198,767 | $21.95 | $4.4M | Through Deerfield Private Design Fund II | Dec 27, 2019 (3d) |
| Dec 24, 2019 | FIXX | ↓ Sell | 151,233 | $21.95 | $3.3M | Through Deerfield Healthcare Innovations | Dec 27, 2019 (3d) |
| Dec 23, 2019 | FIXX | ↓ Sell | 93,551 | $21.78 | $2.0M | Through Deerfield Private Design Fund II | Dec 23, 2019 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LRMR insiders
Open-market trades in the last 12 months
Thomas Edward Hamilton
Insider
2 buys
Jul 6, 2026
Deerfield Mgmt L.P.
Director
1 buy
Feb 27, 2026
Jeffrey W Sherman
Insider
1 buy
Feb 27, 2026
Frank E Thomas
Insider
1 buy
Feb 27, 2026
Deerfield Partners, L.P.
Director
1 buy
Feb 27, 2026
James E Flynn
Director
1 buy
Feb 27, 2026
Deerfield Management Company, L.P.
Director
1 buy
Feb 27, 2026
Deerfield Healthcare Innovations Fund, L.P.
Director
1 buy
Feb 27, 2026
About Deerfield Mgmt III, L.P.'s insider trades
Deerfield Mgmt III, L.P. is a director at Larimar Therapeutics (LRMR). Since Aug 5, 2014, it has reported 85 open-market purchases worth $370.5M and 29 sales worth $61.4M on SEC Form 4. In the last 12 months: 4 buys ($25.0M).
Its filings also include conversions (21 filings), grants and awards (2 filings), other transactions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LRMR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.